🇺🇸 UTHR — United Therapeutics Corporation
Salud CompraPrecio actual
601,32 USD
Máx. histórico
601,32
0 días
Split 2:1 del 23/09/2009
Caída desde máximo
En máximo
Rango 52 semanas
430,02 – 609,99
Variación hoy
+0,87%
Cierre anterior
596,13
Rango de hoy
596,14 – 606,16
Volumen hoy
595.233
Peor caída histórica
-93,18%
12/07/2000 → 10/12/2001
Recuperado en 3311 días
Volatilidad anualizada ⓘ
46,95%
- Nombre completo
- United Therapeutics Corporation
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Drug Manufacturers - Specialty & Generic
- Empleados
- 1.400
- PER ⓘ
- 21,54 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 670,93 USD (puede no estar actualizado)
- Primera cotización
- 17/06/1999
- Precio actualizado
- hace 21 horas
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
| Fecha | Ratio |
|---|---|
| 23/09/2009 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 16/05/2023 | 212,80 | 213,49 | 210,21 | 212,05 | -1,10% | 1,54% | 209.000 |
| 15/05/2023 | 214,19 | 215,38 | 212,80 | 214,40 | +0,18% | 1,20% | 268.200 |
| 12/05/2023 | 214,34 | 214,82 | 212,41 | 214,02 | +0,25% | 1,12% | 328.600 |
| 11/05/2023 | 212,47 | 213,66 | 209,96 | 213,48 | +0,58% | 1,74% | 222.100 |
| 10/05/2023 | 209,84 | 212,75 | 208,23 | 212,24 | +1,26% | 2,15% | 316.600 |
| 09/05/2023 | 209,78 | 211,15 | 208,35 | 209,60 | -0,41% | 1,33% | 376.700 |
| 08/05/2023 | 214,29 | 216,23 | 209,82 | 210,46 | -1,71% | 2,99% | 459.600 |
| 05/05/2023 | 217,48 | 217,79 | 213,23 | 214,12 | -0,74% | 2,10% | 971.700 |
| 04/05/2023 | 219,63 | 219,63 | 211,41 | 215,72 | -1,23% | 3,74% | 674.900 |
| 03/05/2023 | 220,01 | 224,04 | 215,91 | 218,40 | -4,54% | 3,70% | 1.009.500 |
| 02/05/2023 | 232,00 | 232,69 | 227,20 | 228,79 | -1,43% | 2,37% | 594.200 |
| 01/05/2023 | 229,63 | 233,37 | 229,20 | 232,11 | +0,86% | 1,82% | 439.900 |
| 28/04/2023 | 227,71 | 230,64 | 227,37 | 230,13 | +1,06% | 1,44% | 571.100 |
| 27/04/2023 | 225,11 | 228,75 | 223,07 | 227,71 | +0,81% | 2,52% | 215.600 |
| 26/04/2023 | 225,45 | 227,95 | 225,00 | 225,87 | -0,19% | 1,31% | 326.400 |
| 25/04/2023 | 228,29 | 228,40 | 224,20 | 226,31 | -0,87% | 1,84% | 524.700 |
| 24/04/2023 | 229,99 | 231,90 | 227,03 | 228,29 | -1,07% | 2,12% | 416.800 |
| 21/04/2023 | 226,70 | 231,09 | 225,78 | 230,76 | +2,48% | 2,34% | 342.300 |
| 20/04/2023 | 225,17 | 225,91 | 223,06 | 225,17 | -0,67% | 1,27% | 198.300 |
| 19/04/2023 | 227,10 | 228,92 | 224,52 | 226,68 | -0,57% | 1,94% | 221.200 |
| 18/04/2023 | 229,31 | 229,31 | 225,65 | 227,98 | -1,03% | 1,60% | 309.900 |
| 17/04/2023 | 229,96 | 231,74 | 228,77 | 230,35 | +0,71% | 1,29% | 291.300 |
| 14/04/2023 | 231,33 | 232,31 | 227,17 | 228,72 | -1,29% | 2,22% | 233.200 |
| 13/04/2023 | 225,80 | 232,56 | 225,80 | 231,72 | +2,62% | 2,99% | 387.400 |
| 12/04/2023 | 226,99 | 229,11 | 225,23 | 225,80 | -0,22% | 1,71% | 265.500 |
| 11/04/2023 | 222,74 | 228,03 | 222,36 | 226,30 | +1,45% | 2,55% | 340.000 |
| 10/04/2023 | 225,62 | 227,43 | 222,23 | 223,07 | -1,81% | 2,30% | 364.200 |
| 06/04/2023 | 233,22 | 233,83 | 226,29 | 227,19 | -2,49% | 3,23% | 785.600 |
| 05/04/2023 | 228,12 | 233,13 | 227,28 | 232,99 | +2,56% | 2,56% | 534.400 |
| 04/04/2023 | 223,58 | 227,42 | 222,46 | 227,18 | +0,83% | 2,22% | 433.800 |